{"id":90,"date":"2018-05-14T17:02:06","date_gmt":"2018-05-14T21:02:06","guid":{"rendered":"https:\/\/www.secarbitrationlawyer.com\/?p=90"},"modified":"2018-05-14T17:02:06","modified_gmt":"2018-05-14T21:02:06","slug":"menlo-therapeutics-mnlo-i-p-o-losses","status":"publish","type":"post","link":"https:\/\/www.silverlaw.com\/blog\/menlo-therapeutics-mnlo-i-p-o-losses\/","title":{"rendered":"Menlo Therapeutics (\u201cMNLO\u201d) I.P.O. Losses"},"content":{"rendered":"

In January 2018, Menlo Therapeutics went public issuing over 8,000,000 shares of common stock at a public offering price of $17.00 raising over 125 million dollars.\u00a0 NASDAQ lists Menlo\u2019s stock under the ticker symbol \u201cMNLO.\u201d<\/p>\n

Jefferies LLC, Piper Jaffray & Co. and Guggenheim Securities served as the lead underwriters.\u00a0 Menlo\u2019s stock price, MNLO, initially skyrocketed.\u00a0 However, the stock recently plummeted after poor test results costing investors millions of dollars.<\/p>\n

Contact Our Firm if You\u2019ve Invested in Menlo Therapeutics <\/strong>(\u201c<\/strong>MNLO\u201d)<\/strong><\/p>\n

Continue reading \u203a<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

In January 2018, Menlo Therapeutics went public issuing over 8,000,000 shares of common stock at a public offering price of $17.00 raising over 125 million dollars.\u00a0 NASDAQ lists Menlo\u2019s stock under the ticker symbol \u201cMNLO.\u201d Jefferies LLC, Piper Jaffray & Co. and Guggenheim Securities served as the lead underwriters.\u00a0 Menlo\u2019s stock price, MNLO, initially skyrocketed.\u00a0 […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1668],"tags":[1665,1666,1667,1669,1670],"class_list":["post-90","post","type-post","status-publish","format-standard","hentry","category-misrepresentation","tag-guggenheim-securities","tag-jefferies-llc","tag-menlo-therapeutics","tag-mnlo","tag-piper-jaffray-co"],"yoast_head":"\nMenlo Therapeutics (\u201cMNLO\u201d) I.P.O. Losses — Securities Arbitration Lawyers Blog — May 14, 2018<\/title>\n<meta name=\"description\" content=\"In January 2018, Menlo Therapeutics went public issuing over 8,000,000 shares of common stock at a public offering price of $17.00 raising over 125 — May 14, 2018\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.silverlaw.com\/blog\/menlo-therapeutics-mnlo-i-p-o-losses\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Menlo Therapeutics (\u201cMNLO\u201d) I.P.O. Losses — Securities Arbitration Lawyers Blog — May 14, 2018\" \/>\n<meta name=\"twitter:description\" content=\"In January 2018, Menlo Therapeutics went public issuing over 8,000,000 shares of common stock at a public offering price of $17.00 raising over 125 — May 14, 2018\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Silver Law Group\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Menlo Therapeutics (\u201cMNLO\u201d) I.P.O. Losses — Securities Arbitration Lawyers Blog — May 14, 2018","description":"In January 2018, Menlo Therapeutics went public issuing over 8,000,000 shares of common stock at a public offering price of $17.00 raising over 125 — May 14, 2018","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.silverlaw.com\/blog\/menlo-therapeutics-mnlo-i-p-o-losses\/","twitter_card":"summary_large_image","twitter_title":"Menlo Therapeutics (\u201cMNLO\u201d) I.P.O. Losses — Securities Arbitration Lawyers Blog — May 14, 2018","twitter_description":"In January 2018, Menlo Therapeutics went public issuing over 8,000,000 shares of common stock at a public offering price of $17.00 raising over 125 — May 14, 2018","twitter_misc":{"Written by":"Silver Law Group","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.silverlaw.com\/blog\/menlo-therapeutics-mnlo-i-p-o-losses\/#article","isPartOf":{"@id":"https:\/\/www.silverlaw.com\/blog\/menlo-therapeutics-mnlo-i-p-o-losses\/"},"author":{"name":"Silver Law Group","@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/de64d999508b1ad10d608a99f0d2e752"},"headline":"Menlo Therapeutics (\u201cMNLO\u201d) I.P.O. Losses","datePublished":"2018-05-14T21:02:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.silverlaw.com\/blog\/menlo-therapeutics-mnlo-i-p-o-losses\/"},"wordCount":194,"keywords":["Guggenheim Securities","Jefferies LLC","Menlo Therapeutics","MNLO","Piper Jaffray & Co."],"articleSection":["Misrepresentation"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.silverlaw.com\/blog\/menlo-therapeutics-mnlo-i-p-o-losses\/","url":"https:\/\/www.silverlaw.com\/blog\/menlo-therapeutics-mnlo-i-p-o-losses\/","name":"Menlo Therapeutics (\u201cMNLO\u201d) I.P.O. Losses — Securities Arbitration Lawyers Blog — May 14, 2018","isPartOf":{"@id":"https:\/\/www.silverlaw.com\/blog\/#website"},"datePublished":"2018-05-14T21:02:06+00:00","author":{"@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/de64d999508b1ad10d608a99f0d2e752"},"description":"In January 2018, Menlo Therapeutics went public issuing over 8,000,000 shares of common stock at a public offering price of $17.00 raising over 125 — May 14, 2018","breadcrumb":{"@id":"https:\/\/www.silverlaw.com\/blog\/menlo-therapeutics-mnlo-i-p-o-losses\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.silverlaw.com\/blog\/menlo-therapeutics-mnlo-i-p-o-losses\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.silverlaw.com\/blog\/menlo-therapeutics-mnlo-i-p-o-losses\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.silverlaw.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Menlo Therapeutics (\u201cMNLO\u201d) I.P.O. Losses"}]},{"@type":"WebSite","@id":"https:\/\/www.silverlaw.com\/blog\/#website","url":"https:\/\/www.silverlaw.com\/blog\/","name":"Securities Arbitration Lawyers Blog","description":"Published by Securities Arbitration Lawyers \u2014 Silver Law Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.silverlaw.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/de64d999508b1ad10d608a99f0d2e752","name":"Silver Law Group","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9eb0a691642ae95c68ee1c45b5f50f35bae76a41f3d9f861c7bfd40c87661746?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9eb0a691642ae95c68ee1c45b5f50f35bae76a41f3d9f861c7bfd40c87661746?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9eb0a691642ae95c68ee1c45b5f50f35bae76a41f3d9f861c7bfd40c87661746?s=96&d=mm&r=g","caption":"Silver Law Group"}}]}},"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts\/90","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/comments?post=90"}],"version-history":[{"count":0,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts\/90\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/media?parent=90"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/categories?post=90"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/tags?post=90"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}